Free tool
Heavily traded stocks
We cover 56 companies whose typical session turns over more than $10.00M. The median market value in the group is $3.30B. Across the group, the median move over the past trading day is +0.01%. 100% of the 56 with a 200-day average trade above it. Price change over the past year runs from +1.0% to +310.5% across the middle 80 percent of the group, with a median of +64.0%. Across the group, 3 companies currently carry a tier A volume signal.
Other lists in this group
Table
56 of 7,336 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | +86.85% | Oct 29, 2026 |
| AMGN | Amgen Inc. | $238.06B | Mega cap | +56.24% | Nov 3, 2026 |
| TMO | Thermo Fisher Scientific Inc. | $234.31B | Mega cap | +30.17% | Oct 21, 2026 |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% | Oct 22, 2026 |
| BDX | Becton, Dickinson and Company | $51.81B | Large cap | +25.97% | Nov 5, 2026 |
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.59% | Nov 5, 2026 |
| IQV | IQVIA Holdings Inc. | $43.04B | Large cap | +38.51% | Nov 3, 2026 |
| ILMN | Illumina, Inc. | $33.95B | Large cap | +125.88% | Oct 29, 2026 |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +21.14% | Nov 3, 2026 |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% | Oct 20, 2026 |
| GMAB.CO | Genmab A/S | $20.69B | Large cap | +36.19% | Nov 5, 2026 |
| CRL | Charles River Laboratories International, Inc. | $14.09B | Large cap | +81.27% | Nov 4, 2026 |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | +46.30% | Nov 2, 2026 |
| BIO | Bio-Rad Laboratories, Inc. | $10.40B | Large cap | +32.71% | Oct 29, 2026 |
| RGEN | Repligen Corporation | $10.25B | Large cap | +51.67% | Nov 3, 2026 |
| APGE | Apogee Therapeutics, Inc. | $10.21B | Large cap | +257.11% | Nov 9, 2026 |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% | Nov 5, 2026 |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% | Nov 5, 2026 |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% | Nov 4, 2026 |
| HAE | Haemonetics Corporation | $4.85B | Mid cap | +93.71% | Nov 5, 2026 |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% | Nov 11, 2026 |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.84% | Oct 29, 2026 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% | Nov 5, 2026 |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% | Nov 9, 2026 |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% | Nov 5, 2026 |
| OGN | Organon & Co. | $3.62B | Mid cap | +50.67% | Nov 9, 2026 |
| PLSE | Pulse Biosciences, Inc. | $3.43B | Mid cap | +203.47% | Nov 5, 2026 |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.30B | Mid cap | +281.97% | Nov 5, 2026 |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% | Nov 5, 2026 |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% | Nov 5, 2026 |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% | Nov 12, 2026 |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% | Nov 3, 2026 |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% | Nov 5, 2026 |
| BAVA.CO | Bavarian Nordic A/S | $2.51B | Mid cap | −7.97% | Nov 13, 2026 |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% | Oct 27, 2026 |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% | Nov 4, 2026 |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% | Nov 5, 2026 |
| PRGO | Perrigo Company plc | $2.05B | Mid cap | −36.05% | Nov 4, 2026 |
| VIR | Vir Biotechnology, Inc. | $1.87B | Small cap | +111.85% | Nov 4, 2026 |
| BLFS | BioLife Solutions, Inc. | $1.82B | Small cap | +45.50% | Nov 5, 2026 |
| INBX | Inhibrx Biosciences, Inc. | $1.81B | Small cap | +357.45% | Nov 13, 2026 |
| ETON | Eton Pharmaceuticals, Inc. | $1.79B | Small cap | +262.38% | Nov 12, 2026 |
| FBRX | Forte Biosciences, Inc. | $1.63B | Small cap | +589.87% | Nov 9, 2026 |
| CGEM | Cullinan Therapeutics, Inc. | $1.48B | Small cap | +188.15% | Nov 5, 2026 |
| AMBEA.ST | Ambea AB (publ) | $1.45B | Small cap | +38.66% | Nov 4, 2026 |
| ANRO | Alto Neuroscience, Inc. | $1.43B | Small cap | +786.65% | Nov 11, 2026 |
| OMER | Omeros Corporation | $1.40B | Small cap | +328.71% | Nov 12, 2026 |
| CHEMM.CO | ChemoMetec A/S | $1.33B | Small cap | −3.94% | Sep 10, 2026 |
| 6523.T | PHC Holdings Corporation | $1.21B | Small cap | +58.42% | Nov 11, 2026 |
| JANX | Janux Therapeutics, Inc. | $1.15B | Small cap | −19.10% | Nov 5, 2026 |
| HELP | Cybin D/B/A Helus Pharma | $995.81M | Small cap | +77.71% | Nov 12, 2026 |
| ACHV | Achieve Life Sciences, Inc. | $851.00M | Small cap | +177.52% | Nov 5, 2026 |
| AQST | Aquestive Therapeutics, Inc. | $676.51M | Small cap | +40.00% | Nov 4, 2026 |
| SGMT | Sagimet Biosciences Inc. | $675.04M | Small cap | +39.59% | Nov 12, 2026 |
| CRNA.OL | Circio Holding ASA | $384.19M | Small cap | +1733.85% | Aug 31, 2026 |
| SOON.SW | Sonova Holding AG | — | — | +6.01% | Nov 12, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.